Adenoviral-mediated over-expression of Brn2 in the rat paraventricular nucleus: no effect on vasopressin or corticotrophin releasing factor RNA levels.
We have used an over-expression strategy to test the hypothesis that the Class III POU transcription factor Brn2 is rate limiting in the control of the level of expression of the vasopressin (VP) gene in the paraventricular nucleus of the rat hypothalamus. Knockout studies in mice have suggested that Brn2 may contribute to the control of the level of VP gene expression in the adult hypothalamus. However, we show here that in heterologous cell lines, Brn2 transactivates neither the proximal promoter of the rat VP gene, nor a novel reporter construct consisting of the rat VP structural gene and 3 and 2 kbp of upstream and downstream flanking sequences. We hypothesised that this maybe due either to the lack of cis-acting elements within the confines of the reporter vectors used, or to the absence in heterologous cells, of factors required for Brn2 activity. As no cell lines exist that correspond to VP neurons, we devised an adenoviral vector delivery strategy that enabled efficient over-expression of Brn2 in the paraventricular nucleus of the intact rat. Localised over-expression of Brn2 had no effect on VP hnRNA levels. Neither did we detect corticotrophin releasing factor (CRF) mRNA up-regulation by Brn2 over-expression in vivo. This was unexpected as Brn2 transactivates the proximal CRF promoter in vitro. Whilst Brn2 is required for the development of the hypothalamic structures that express VP and CRF, these data suggest that this transcription factor is not required, or is not rate limiting, for expression in the adult.
Wong
Liang-Fong
LF
University Research Centre for Neuroendocrinology, Bristol Royal Infirmary, University of Bristol, Marlborough street, UK.
Murphy
David
D
D000256:Adenoviridae / Q000235:genetics*; D000328:Adult; D000818:Animals; D002460:Cell Line; D045744:Cell Line, Tumor; D003346:Corticotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation; D005822:Genetic Vectors / Q000235:genetics; D018398:Homeodomain Proteins; D006801:Humans; D051379:Mice; D008957:Models, Genetic; D050809:POU Domain Factors; D010286:Paraventricular Hypothalamic Nucleus / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism* / Q000502:physiology; D014667:Vasopressins / Q000235:genetics / Q000378:metabolism*
D018398:Homeodomain Proteins; D050809:POU Domain Factors; D012333:RNA, Messenger; D014157:Transcription Factors; C085076:transcription factor Brn-2; D014667:Vasopressins; D003346:Corticotropin-Releasing Hormone